Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle against Non-Small Cell Lung Cancer

1. Explain the molecular mechanism of action of vascular disrupting agents. Evaluate the preclinical results of vascular disrupting agents. 3. Assess the preliminary clinical results of vascular disrupting agents in the treatment of patients with NSCLC. This article is available for continuing medical education credit at CME.TheOncologist.com. The aim of this review is to discuss the hypothesized molecular mechanisms of action of VDAs and their early preclinical and clinical results, emphasizing ASA404, combretastatin A-4 disodium phosphate, ABT-751, and NPI-2358, reported in the treatment of non-small cell lung cancer, which is the leading cause of cancer death worldwide, and also to discuss future developments in this cancer population. The Oncologist CME CME ABSTRAC